
In this episode of Inside Biotech, we sit down with Ailin Zhang, a UC Irvine PhD candidate and member of the BCLA Consulting team, to explore biotech investment trends across the U.S. in 2026. We discuss shifts in early- and late-stage venture funding, the rise of licensing and M&A activity, growing investment in AI and biologics, and changing trends across therapeutic modalities. Ailin also shares insights from BCLA’s Card News research and discusses what these trends could mean for biotech startups, investors, consultants, and the future of innovation.
BCLA Card News: https://www.bc-la.org/about-3
Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!
To learn more about BCLA’s events and consulting visit our website.
Follow BCLA on LinkedIn
D'autres épisodes de "Inside Biotech"



Ne ratez aucun épisode de “Inside Biotech” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.








